

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock code: 1093)

VOLUNTARY ANNOUNCEMENT

SELECTION RESULTS OF NATIONAL CENTRALISED MEDICINES PROCUREMENT

This announcement is made by CSPC Pharmaceutical Group Limited (the “**Company**”, and together with its subsidiaries, the “**Group**”) on a voluntary basis.

The Company hereby announces that 3 products of the Group (the “**Products**”) are being selected in the tender for national centralised procurement of medicines in China, details of the relevant selection results are stated below:

Product	Specification and Packaging	Pricing Unit	Selected Price (RMB Yuan)	Supplying Province
Amoxicillin Capsules	0.25g * 30 capsules	Box	2.16	Inner Mongolia, Zhejiang, Sichuan, Tibet, Shaanxi
Azithromycin Tablets	0.25g * 6 tablets	Box	4.98	Beijing, Tianjin, Zhejiang, Hunan, Guangdong, Guizhou, Shaanxi, Qinghai, Xinjiang (including the Corps)

Product	Specification and Packaging	Pricing Unit	Selected Price (RMB Yuan)	Supplying Province
Paclitaxel for Injection (albumin-bound)	100mg * 1 vial	Box	747	Hebei, Shanxi, Liaoning, Jilin, Heilongjiang, Jiangsu, Hunan, Guangdong, Guizhou, Shaanxi, Qinghai

The other 2 products of the Group namely, Clindamycin Hydrochloride Capsules and Cephalexin Capsules, have not been successfully selected under the tender.

The selected prices of each of the Products under the tender are lower than their respective current selling prices in the market. Nonetheless, the Company considers that the Products being successfully selected under the tender will be conducive to expanding sales volume of those products.

By order of the Board
CSPC Pharmaceutical Group Limited
Cai Dongchen
Chairman

Hong Kong, 18 January 2020

As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LU Hua, Dr. LI Chunlei, Dr. WANG Qingxi and Mr. CHAK Kin Man as executive directors; Mr. LEE Ka Sze, Carmelo as non-executive director; and Mr. CHAN Siu Keung, Leonard, Mr. WANG Bo, Prof. LO Yuk Lam, Dr. YU Jinming and Mr. CHEN Chuan as independent non-executive directors.